Christine L. Hale

Most-cited papers

1. Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults

   R. Townsend, A. Dietz, Christine L. Hale, S. Akhtar +8 more

   2016Clinical pharmacology in drug development106 citations Open access

   Semantic Scholar

   Save

2. Combined interstitial hyperthermia and brachytherapy: Institute Gustave Roussy technique and preliminary results.

   J. Cosset, J. Dutreix, J. Dufour, P. Janoray +3 more

   1984International Journal of Radiation Oncology, Biology, Physics51 citations

   Semantic Scholar

   Save

3. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia

   Madhu Sanga, Joyce K. James, Joseph Marini, G. Gammon +2 more

   2017Xenobiotica; the fate of foreign compounds in biological systems29 citations

   Semantic Scholar

   Save

4. Two Phase 1, Open‐Label, Mass Balance Studies to Determine the Pharmacokinetics of 14C‐Labeled Isavuconazonium Sulfate in Healthy Male Volunteers

   R. Townsend, Kota Kato, Christine L. Hale, D. Kowalski +4 more

   2017Clinical pharmacology in drug development24 citations Open access

   Semantic Scholar

   Save

5. Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs

   Alec O'Keeffe, Christine L. Hale, J. Cotton, V. Yardley +4 more

   2020Microorganisms19 citations Open access

   Semantic Scholar

   Save

6. Absorption, Metabolism, and Excretion of [14C]‐Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open‐Label, Mass‐Balance Study

   Monette M. Cotreau, Christine L. Hale, L. Jacobson, Claudine S. Oelke +5 more

   2012Clinical pharmacology in drug development10 citations

   Semantic Scholar

   Save

7. Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers

   Jian-Ke Li, G. Bresnahan, G. Gammon, Madhu Sanga +4 more

   20125 citations

   Semantic Scholar

   Save

8. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects

   D. Small, J. Royalty, E. Cannady, Christine L. Hale +3 more

   2016Pharmacotherapy4 citations Open access

   Semantic Scholar

   Save

9. Abstract C123: A phase 1 study to evaluate the absorption, metabolism, and excretion of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) tivozanib.

   M. Cotreau, Christine L. Hale, L. Jacobson, Claudine Oelke +4 more

   20113 citations

   Semantic Scholar

   Save

10. AIDS: Disease Characteristics and Attributions of Sympathy and Blame.

    Christine L. Hale, M. Watson

    19890 citations

    Semantic Scholar

    Save